Assessment of confounding factors affecting the tumor markers SMRP, CA125, and CYFRA21-1 in serum

Biomarker Insights

Volumn 2010, Issue 5, 2010, Pages 1-8

  Weber, Daniel Gilbert ^a   Johnen, Georg ^a   Taeger, Dirk ^a   Weber, Anne ^a   Gross, Isabelle Mercedes ^a   Pesch, Beate ^a   Kraus, Thomas ^b   Brüning, Thomas ^a   Gube, Monika ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

CA125; CYFRA21 1; Lung cancer; Mesothelin; Mesothelioma; Screening; SMRP

Indexed keywords

ASBESTOS; CA 125 ANTIGEN; CREATININE; CYTOKERATIN 19 FRAGMENT; SOLUBLE MESOTHELIN RELATED PEPTIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; OCCUPATIONAL EXPOSURE; PROTEIN BLOOD LEVEL;

EID: 77951283497     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s3927     Document Type: Article

References (26)

1. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79(3-4):666-672.
2. Scherpereel A, Lee YG. Biomarkers for mesothelioma. Curr Opin Pulm Med. 2007;13(4):339-443.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-44.
4. Lowe KA, Shah C, Wallace E, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2480-7.
5. Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem. 2007;53(4):666-72.
6. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med. 2008;178(8):832-7.
7. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362(9396):1612-6.
8. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007;13(17):5076-81.
9. Paganuzzi M, Onetto M, Marroni P, et al. Diagnostic value of CYFRA21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest. 2001;119(4):1138-42.
10. Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126(6):1757-63.
11. Nagele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rodiger W. CA125 and its relation to cardiac function. Am Heart J. 1999;137(6):1044-9.
12. Fraser CG. Inherent biological variation and reference values. Clin Chem Lab Med. 2004;42(7):758-64.
13. Weber DG, Taeger D, Pesch B, Kraus T, Bruning T, Johnen G. Soluble mesothelin-related peptides (SMRP)-High stability of a potential tumor marker for mesothelioma. Cancer Biomark. 2007;3(6):287-92.
14. Marczynski B, Rozynek P, Kraus T, Schlosser S, Raithel HJ, Baur X. Levels of 8-hydroxy-2'-deoxyguanosine in DNA of white blood cells from workers highly exposed to asbestos in Germany. Mutat Res. 2000;468(2): 195-202.
15. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and Meso-thelin Levels for the Diagnosis of Malignant Mesothelioma. Chest. 2007;132(4):1239-46.
16. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13(10):2928-35.
17. Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med. 2007;45(5):634-8.
18. Fuhrman C, Duche JC, Chouaid C, et al. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem. 2000;33(5):405-10.
19. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2008;85(1):265-72; discussion 272.
20. Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev. 2009;18(2): 646-50.
21. Hillerdal G. Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest. 1983;77(4):321-43.
22. Hollevoet K, Bernard D, De Geeter F, et al. Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin Chem. 2009;55(7):1431-3.
23. Tramonti G, Ferdeghini M, Donadio C, et al. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA21-1, TPA, and TPS) in patients without evidence of neoplasia. Cancer Detect Prev. 2000;24(1):86-90.
24. Thorpe JD, Duan X, Forrest R, et al. Effects of blood collection conditions on ovarian cancer serum markers. PLoS ONE. 2007;2(12):e1281.
25. Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer. 2008;61(2):235-43.
26. Gao YC, Yuan ZB, Yang YD, Lu HK. Effect of freeze-thaw cycles on serum measurements of AFP, CEA, CA125 and CA19-9. Scand J Clin Lab Invest. 2007;67(7):741-7.